Teva Pharmaceutical Industries (TEVA) Minority Interest (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Minority Interest for 18 consecutive years, with $4.0 million the latest figure, recorded in Q1 2026.

• Quarterly Minority Interest fell 42.86% year-over-year to $4.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.0 million (down 42.86% YoY) and the FY2025 annual result came in at $4.0 million, down 98.82% from the prior year.
• Minority Interest steadied at $4.0 million in Q1 2026 per TEVA's latest filing, from $4.0 million in the prior quarter.
• Over the last five years, Minority Interest for TEVA reached as high as $916.0 million in Q1 2022 and fell as low as $4.0 million in Q3 2025.
• A 5-year average of $412.6 million and a median of $340.0 million in 2024 frame the typical range for Minority Interest.
• Annual changes were most pronounced in 2022 — Minority Interest slipped 6.05% — and 2025, when it sank 98.82%.
• Year by year, Minority Interest stood at $794.0 million in 2022, then fell by 21.91% to $620.0 million in 2023, then tumbled by 45.16% to $340.0 million in 2024, then plunged by 98.82% to $4.0 million in 2025, then changed by 0.0% to $4.0 million in 2026.
• According to Business Quant data, Minority Interest over the past three periods registered $4.0 million, $4.0 million, and $4.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.